complement 5a receptor (c5ar)

W-54011 is a potent non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils (Ki: 2.2 nM). W-54011 inhibits C5a-induced intracellular Ca2+ mobilization, chemotaxis, and generation of ROS in human neutrophi

Avacopan (CCX168) is a C5aR antagonist (IC50=0.1 nM) with selective and oral activity. Avacopan blocks the action of C5a and prevents the development of GN induced by anti-myeloperoxidase antibodies in a mouse model of AAV. Avacopan can be used to treat anti-neutrophil cytoplasmic antibody (ANCA)-related vasculitis.

PMX 205 acetate is an antagonist of complement C5a receptor (C5aR; CD88).

NDT 9513727 is a potent, selective, and competitive C5aR1 inverse agonist used in the study of inflammatory and immune disorders.

CP-447697, a lipophilic C5a receptor antagonist, exhibits an IC50 of 31 nM. It is utilized in inflammation research.

CP-289 is a potent C5a receptor antagonist with IC50 of 1 μM.

Tesidolumab (LFG316) is a fully human IgG1 λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cutting of C5 and preventing the subsequent formation of membrane attack complex, which can be used to study extravascular hemolysis.

Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

LEP(116-130)(mouse) is a synthetic leptin peptide fragment.

PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).